Development Event Based Payments Sample Clauses
Development Event Based Payments. If Roche (alone or with its Affiliates) develops a Non-Memory Compound for a Neurological Indication or a Psychiatric Indication, then Roche shall pay Memory for such Non-Memory Compound achieving the Events of Sections 4.3(a) and 4.3(b) as if such Non-Memory Compound were a Product except (i) Roche shall pay [*] percent ([*]%) of such payments related to IND, Phase II and Phase III Events, and (ii) [*] percent ([*]%) of all other payments provided under Section 4.3(a) and 4.3(b). If Roche (alone or with its Affiliates) develops a Non-Memory Compound for an Other Indication, then Roche shall pay Memory for such Non-Memory Compound achieving the Events of Sections 4.3(c) as if such Non-Memory Compound were a Product except (i) Roche shall pay [*] percent ([*]%) of such payments related to IND, Phase II and Phase III Events, and (ii) [*] percent ([*]%) of all other payments provided under Section 4.3(c). Each payment in this Schedule C shall be due and payable by Roche within thirty (30) days after occurrence of the applicable Event. Roche will make each of such payments only once, for the first occurrence of a respective Event, regardless of how many times the Event may be subsequently achieved with a Non-Memory Compound. An Event shall be deemed to have occurred regardless of whether a Product or a Non-Memory Compound first achieved the Event.
Development Event Based Payments. Based upon this event occurring on or before [*]. If this event occurs after such date, the payment shall be reduced to [*] dollars ($[*]). ** Based upon this event occurring on or before [*]. If this event occurs after such date, the payment shall be reduced to [*] dollars ($[*]). *** If any Product is for a Psychiatric Indication other than schizophrenia, then the payment shall be reduced to [*] dollars ($[*]). [*] CONFIDENTIAL TREATMENT IS REQUESTED
(a) Neurological Indications. Roche shall pay to Memory with respect to such Product the following non-refundable and non-creditable payments upon the first occurrence of the following events for such Product if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which any payment has been made under Section 4.4(b) or 4.4(c): -------------------------------------------------------------- EVENT PAYMENT (MIO US$) -------------------------------------------------------------- [*] (or a foreign equivalent) [*] for a Neurological Indication -------------------------------------------------------------- [*] for a Neurological Indication [*] -------------------------------------------------------------- [*] for a Neurological Indication [*] --------------------------------------------------------------
(b) Psychiatric Indications. Roche shall pay to Memory with respect to such Product the following non-refundable and non-creditable payments upon the first occurrence of the following events for such Product if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which any payment has been made under Section 4.4(a) or 4.4(c): -------------------------------------------------------------- EVENT PAYMENT (MIO US$) -------------------------------------------------------------- [*] (or foreign equivalent) for [*] a Psychiatric Indication -------------------------------------------------------------- [*] for a Psychiatric Indication [*] -------------------------------------------------------------- [*] for a Psychiatric Indication [*] --------------------------------------------------------------
Development Event Based Payments. Based upon this event occurring on or before [*]. If this event occurs after such date, the payment shall be reduced to [*] dollars ($[*]). ** Based upon this event occurring on or before [*]. If this event occurs after such date, the payment shall be reduced to [*] dollars ($[*]). *** If any Product is for a Psychiatric Indication other than schizophrenia, then the payment shall be reduced to [*] dollars ($[*]). [*] CONFIDENTIAL TREATMENT IS REQUESTED
(a) Neurological Indications. Roche shall pay to Memory with respect to such Product the following non-refundable and non-creditable payments upon the first occurrence of the following events for such Product if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which any payment has been made under Section 4.4(b) or 4.4(c): EVENT PAYMENT (MIO US$) ----- ----------------- [*] (or a foreign equivalent) for a Neurological [*] Indication [*] for a Neurological Indication [*] [*] for a Neurological Indication [*]
(b) Psychiatric Indications. Roche shall pay to Memory with respect to such Product the following non-refundable and non-creditable payments upon the first occurrence of the following events for such Product if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which any payment has been made under Section 4.4(a) or 4.4(c): EVENT PAYMENT (MIO US$) ----- ----------------- [*] (or foreign equivalent) for a Psychiatric Indication [*] [*] for a Psychiatric Indication [*] [*] for a Psychiatric Indication [*]
Development Event Based Payments